Marc Dunoyer, Alexion CEO

As­traZeneca wa­gers on $500M buy­out, plucks PhI­II drug for Alex­ion’s rare dis­ease pipeline — and jumps straight in­to risky field

Marc Dunoy­er has un­veiled his first buy­out since tak­ing over at Alex­ion — one that his pre­de­ces­sors have las­soed in be­fore a $39 bil­lion merg­er made the rare dis­ease spe­cial­ist a part of As­traZeneca.

The deal adds an­oth­er drug to Alex­ion’s late-stage pipeline, which is heav­i­ly pop­u­lat­ed by can­di­dates sourced through M&A and li­cens­ing pacts.

It al­so takes As­traZeneca in­to a risky dis­ease that has blown up ef­forts by Prothena and Glax­o­SmithK­line.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.